RE: amorakBut the share price was not fueled by pure speculation. You're engaging in hyperbole to suggest it. There is actual and perceived value in RVX. The financing north of $10 proved that. Oppenheimer and Caris bought that financing for good reason.
The parade of pharmas visiting Calgary suggest value. Esperion's buyout proved value. The engagement of UBS indicates a belief in value on RVX's part. The presence of Shah, Rader, Barter, Genest, etc. suggest value. The science that we know of suggests value. The various trials and studies that show the importance of Apo-A1 indicate value.
There was and will again be a premium for the imminence of a deal. But that's up at $30. It would require a major reason to doubt the science for this to drop again to $5. That's evident by the volume when this drops to $10 to $12.
Very comfortable here, coorsman.